Posted by Michael Wonder on 04 Oct 2023
Galderma announces progress with relabotulinumtoxinA regulatory submissions
2 October 2023 - Galderma receives FDA complete response letter with comments isolated to Chemistry, Manufacturing, and Controls items.
Galderma announced today updates related to the regulatory progress of its pending biologics license application for relabotulinumtoxinA (QM-1114) to the US FDA.
